Ipca Laboratories Limited (NSE:IPCALAB)
India · Delayed Price · Currency is INR | Market Cap | 386.75B +11.9% |
| Revenue (ttm) | 98.21B +9.8% |
| Net Income | 11.41B +54.7% |
| EPS | 44.98 +54.7% |
| Shares Out | 253.70M |
| PE Ratio | 33.89 |
| Forward PE | 27.32 |
| Dividend | 4.00 (0.26%) |
| Ex-Dividend Date | Aug 5, 2025 |
| Volume | 979,178 |
| Open | 1,576.90 |
| Previous Close | 1,572.40 |
| Day's Range | 1,483.50 - 1,618.70 |
| 52-Week Range | 1,251.60 - 1,678.30 |
| Beta | 0.07 |
| Analysts | Buy |
| Price Target | 1,676.82 (+10.0%) |
| Earnings Date | May 29, 2026 |
About Ipca Laboratories
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, a... [Read more]
Financial Performance
In fiscal year 2026, Ipca Laboratories's revenue was 98.21 billion, an increase of 9.84% compared to the previous year's 89.41 billion. Earnings were 11.41 billion, an increase of 54.69%.
Financial StatementsNews
Ipca Laboratories Quarterly report: Q4 2026
Ipca Laboratories has published its Q4 2026 quarterly earnings report on June 1, 2026.
Top stocks to buy: Stock recommendations for March 30, 2026 week - check list
Stock market recommendations: Ipca Laboratories, and AU Small Finance Bank are the stocks that Motilal Oswal Wealth Management Research Desk recommends buying for the week starting March 30, 2026. Tar...
Top stocks to buy: Stock recommendations for March 23, 2026 week - check list
Stock market recommendations: Ipca Laboratories, and Hindalco are the top stocks that Motilal Oswal Wealth Management Research Desk has picked for this week starting March 23, 2026.
Ipca Laboratories Transcript: Q3 25/26
Q3 saw 6.5% revenue growth and improved EBITDA margins, with strong domestic and export performance, especially in chronic therapies and West Africa. Unichem margins remain under pressure but are expected to recover as new launches and filings mature.
Ipca Laboratories Quarterly report: Q3 2026
Ipca Laboratories has published its Q3 2026 quarterly earnings report on February 16, 2026.
Ipca Laboratories Q3 Results: Net profit jumps 31.5% YoY to Rs 326.27 crore, revenue up 6.55%
Ipca Laboratories reported a steady performance for the quarter ended December 31, 2025, with profit growth outpacing revenue expansion on...
Ipca Laboratories receives US FDA VAI status for Tarapur API facility
Ipca Laboratories has received a positive regulatory update from the United States Food and Drug Administration (US FDA) for its...
This brokerage firm advises to Buy IPCA Labs shares and expects nearly 20% upside in stock price
Emkay Global has initiated coverage on Ipca Laboratories with a buy rating and a target price of ₹1,700 per share,...
Ipca Laboratories Transcript: Q2 25/26
Domestic and API businesses delivered strong growth, with EBITDA margins improving year-over-year. Export formulations faced headwinds, but guidance for H2 remains positive, and Unichem's performance is recovering. R&D spend will stay elevated as the company builds its global pipeline.
Ipca Laboratories Quarterly report: Q2 2026
Ipca Laboratories has published its Q2 2026 quarterly earnings report on November 13, 2025.
Ipca Laboratories Q2 FY26 results: Revenue up 9% YoY to Rs 2,556.5 crore, Net profit rises 23%
Ipca Laboratories Ltd reported a 9% year-on-year growth in revenue from operations at Rs 2,556.50 crore for Q2 FY26, compared...
Ipca and BioSimilar Sciences sign Technology Transfer Agreement for next-gen cancer and anti-inflammatory biosimilar
Ipca Laboratories Ltd. (NSE: IPCA) and BioSimilar Sciences PR LLC (BSS) today announced a definitive Technology Transfer and Joint Development Agreement. As part of the deal, the late-stage developmen...
Ipca Laboratories Transcript: Q1 25/26
Domestic and export businesses delivered double-digit growth, with strong gains in chronic and acute segments. Standalone margins improved, but consolidated EBITDA margin guidance was trimmed due to Unichem's challenges, including one-time provisions and market share losses.
Ipca Laboratories Quarterly report: Q1 2026
Ipca Laboratories has published its Q1 2026 quarterly earnings report on August 12, 2025.
Ipca Laboratories Q1 results: Net profit surges 21% YoY to Rs 233.21 crore, revenue up 10.3%
Ipca Laboratories Limited posted a consolidated net profit attributable to owners of the company at Rs 233.21 crore for the quarter ended June 30, 2025, marking a 21% increase from Rs 192.24 crore in ...
Top Q1 results today, August 11: SJVN, BEML, Bata India, Titagarh Rail, Ipca Laboratories and more to announce earnings
The earnings season continues to heat up as Monday, August 11, 2025, will see a busy line-up of companies reporting their financial results for the first quarter of FY26. From large-cap names to mid a...
IPCA Laboratories shares dip over 2% after HSBC cuts target price to Rs 1,330
IPCA Laboratories Ltd. shares fell more than 2% in early trading following HSBC’s downgrade of the stock’s target price to ₹1,330 per share. The brokerage maintained a Hold rating on the stock, reflec...
Ipca Laboratories Transcript: Q4 24/25
Domestic and export businesses delivered double-digit growth, with EBITDA margins improving across segments. New manufacturing facilities and ongoing Unichem integration are set to drive future growth, while guidance remains conservative at 8-10% revenue growth and 1% margin expansion for FY26.
Ipca Laboratories Annual report: Q4 2025
Ipca Laboratories has published its Q4 2025 annual report on May 30, 2025.
Ipca Laboratories Quarterly report: Q4 2025
Ipca Laboratories has published its Q4 2025 quarterly earnings report on May 30, 2025.
IPCA Laboratories Q4 results: Revenue jumps 10.50% YoY to Rs 2,247 crore, net profit up 14.1% YoY
IPCA Laboratories has announced its financial results for the fourth quarter, showing moderate year-on-year growth across key indicators. The company reported a net profit of ₹68 crore, compared to ₹5...
Ipca Laboratories to sell it Tarapur manufacturing facility for Rs 36.90 crore
Ipca Laboratories Ltd. has announced the sale of its formulations manufacturing facility in Tarapur, Palghar, for ₹36.90 crore. The decision aligns with the company’s strategy to optimize manufacturin...
Ipca Laboratories Transcript: Q3 24/25
EBITDA margins and gross margins reached record highs, driven by improved product mix, strong chronic and ROW market growth, and operational efficiencies. Domestic and EU businesses outperformed the market, while Unichem's integration boosted consolidated margins. Net debt is set to be eliminated next year.
Ipca Laboratories Quarterly report: Q3 2025
Ipca Laboratories has published its Q3 2025 quarterly earnings report on February 13, 2025.
Ipca Laboratories shares surge over 4% on strong Q3 results, EBITDA beats estimates
Ipca Laboratories Limited saw its stock price rise over 4% on February 13 following a robust financial performance in Q3 FY25, surpassing market estimates on key profitability metrics. The company’s r...